B. Riley Securities Maintains Buy on Ovid Therapeutics, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Kalpit Patel maintains a Buy rating on Ovid Therapeutics (NASDAQ:OVID) but lowers the price target from $9 to $3.
June 18, 2024 | 3:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
B. Riley Securities maintains a Buy rating on Ovid Therapeutics but significantly lowers the price target from $9 to $3, indicating a more cautious outlook.
The significant reduction in the price target from $9 to $3 suggests a more cautious outlook on Ovid Therapeutics' future performance, which could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100